Evgen Pharma Share Discussion Threads

[bumpa33] 09/5/2021 16:42

Ha, well it is the market hence you’re gonna encounter a “few” of them over time.

As we’re moving through the qtr I’m beginning to get excited.

[moneymunch] 09/5/2021 16:19

Lol Bumpa, also reminiscent of a few know it alls, who think they know it all...ho ho...:-)))

[moneymunch] 09/5/2021 16:07

25th March 2021 - John Hopkins University of Medicine, Baltimore USA

“The similar results observed between the coronaviruses evaluated suggest that SFN could have broad activity against coronaviruses, a feature that may prove invaluable as new strains of pathogenic coronaviruses enter the human population.”

Conclusion

We documented that SFN can inhibit the in vitro and in vivo replication of SARS-CoV-2 at pharmacologically and therapeutically achievable doses and can modulate the inflammatory response thereby decreasing the consequences of infection in the animal model when administered prior to infection. Given that SFN is orally bioavailable, commercially available, and has limited side-effects, our results suggest it could be a promising and easily scalable approach for the prevention and treatment of COVID-19 as well as other coronavirus infections.

[moneymunch] 09/5/2021 15:51

Scientists have said it will probably take years to develop a bespoke drug of this kind, explaining there has been a lack of investment in this field in recent decades. This also calls into question Downing Street’s recent plans to deliver two effective antiviral treatments to the population by autumn.

[moneymunch] 09/5/2021 15:39

SFX-01 appears to be completely under the radar from mainstream opinion on finding a home pill treatment/ prevention...yet efficacy assessment data is expected imminently...positive data must see SFX 01 as prime candidate for Boris's Covid treatment taskforce, and may be planet Earths thereafter if efficacy data anywhere near correlates to John Hopkins University research on Sulforaphane as a promising agent for prevention as well as treatment....Gla Holders...Exciting times for all invested. :-)

[moneymunch] 08/5/2021 14:40

News/UPdate on SFX-01's Breast Cancer programme at anytime. Gla ;-)

Rob Clarke
@RobClarkeLab
·
3h
Check out our @MCRBreastCentre report for 2019-2020 to find out how we’re translating basic and clinical breast research into patient benefit. Mancunian research academics doing #teamscience = better research

· May 7
We are thrilled to present the latest MBC Report for 2019-2020 which highlights our recent breast research and publications.



......................


The major research interests of the group are breast development, where we focus on hormonal regulation of luminal progenitors and cancer where bone metastasis and endocrine resistance are major interests.

Recently, we established a role for the human bone microenvironment in promoting colonisation of breast cancer cells through secretion of interleukin 1 beta (IL1β). We showed that IL1β induces Wnt signalling in the cancer cells and that drives colony-forming activity using novel models of patient-derived bone marrow and breast cancer cells (Refs 1 & 2).

Our research on estrogen receptor-positive (ER+) breast cancer aims to identify drivers of resistance to current standard of care treatments including endocrine and CDK4/6 inhibitor therapies.

We previously established that ALDH+ cancer stem cells (CSCs) were responsible for anti-estrogen resistance driven by Notch4 receptor signalling (Simoes et al., Cell Reports, 2015), and more recently have shown that this is inhibited by peptides derived from FKBPL protein (3).

We also exploited patient-derived samples from endocrine resistant patients to demonstrate a role for PAK4 kinase in resistance and validated the efficacy of a potent kinase inhibitor currently licenced by Cancer Research UK Commercial Partnerships (4). In exciting work published in Oncogene (5), we showed that endocrine resistant ALDH+ CSCs from patients could be inhibited by a stabilised formulation of sulforaphane (SFX-01).

This research led from ‘bench to bedside’ providing the basis for the clinical trial (STEM01) in metastatic breast cancer led by MBC Medical Oncologist Sacha Howell. Finally, we used single cell gene expression analysis of endocrine resistant CSCs to establish that there is a dormant population of cells remaining after treatment that are dependent on the IL1β signalling pathway (6).

This links to our work in bone metastasis outlined above which indicates that endocrine resistant CSCs will respond to the bone microenvironment and may be sensitive to IL1β inhibitors such as Anakinra and Canakinumab. We hope our MBC clinical colleagues will test this in future clinical trials.

Simões BM, Santiago-Gómez A, Chiodo C, Moreira T, Conole D, Lovell S, Alferez D, Eyre R, Spence K, Sarmiento-Castro A, Kohler B, Morisset L, Lanzino M, Andò S, Marangoni E, Sims AH, Tate E, Howell SJ and Clarke RB.

Targeting STAT3 signalling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer. Oncogene. 2020 May 30.



................................

Dr Howell and Prof Clarke are both on Evgen's Scientific Advisory Board.

In addition, Dr Howell also works closely with the Breast Biology Group of Professor Rob Clarke and has translated the findings of the group into successful treatment trials, with publications expected in 2021

[bumpa33] 08/5/2021 13:26

Thanks OT.

[on target] 07/5/2021 15:14

Double-blind.

[bumpa33] 07/5/2021 15:14

You’re welcome garth, we’ve got some good contributors on here now, and since the new thread was started, none of the bickering thank god.

[garth] 07/5/2021 15:05

Thank you for the content you have been posting. I am mostly silent but I am following and appreciating.

G.

[bumpa33] 07/5/2021 15:04

Nearly half way through the quarter, could be any time now, or the last bloody day in June...!

[bumpa33] 07/5/2021 15:02

Very witty garth ;)

[garth] 07/5/2021 14:59

Bumpa,

from the share price one might think completely blind. Trial? What trial?

Ho-hum.

I took up my rights and keep nibbling at more now and then.

And I keep thinking, maybe this week? Not much of the second quarter left...

G.

[bumpa33] 07/5/2021 14:55

I’ve forgotten, is the trial blind or double blind..?

[pdt] 07/5/2021 10:52

Thanks for posting The Lancet link On target

[pdt] 07/5/2021 10:32

New article in The Lancet which is an overview of the COVID problem;

The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity

(you will need to search for it because it will not let me post the link)

In the conclusion and of relevance to us is the following;

"Endothelial and epithelial infection appears to predominate, rather than alveolar-centred infection: the disruption of the alveolar epithelial–endothelial barrier is central to the development of severe pneumonia and ARDS."

There are a number of papers on how upregulation of NRF2 helps in this area such as;

"MitoQ protects against hyperpermeability of endothelium barrier in acute lung injury via a Nrf2-dependent mechanism"



And

Activating the Nrf2-mediated antioxidant response element restores barrier function in the alveolar epithelium of HIV-1 transgenic rats



And finally with a weekend about to start perhaps they will lock the database and unblind the data giving us news on Monday? We must be very close to news.

[amaretto1] 07/5/2021 07:38

MXC very interesting results ... RNS

[moneymunch] 06/5/2021 21:51

Lol, presumably Wikipedia are waiting for validation of efficacy along with the market. Gl :-)

[bumpa33] 06/5/2021 20:00

Hmm, sure they’d love that as it’s a US entity.

[muddy_40] 06/5/2021 19:52

Should maybe add the John Hopkins publication. And mention that write up. That's not really promotion I would think?

[bumpa33] 06/5/2021 19:32

Hmm, someone didn’t like my (wikipedia) sulforaphane update.


Please do not add promotional material to Wikipedia, as you did to Sulforaphane. While objective prose about beliefs, organisations, people, products or services is acceptable, Wikipedia is not a vehicle for soapboxing, advertising or promotion. Thank you. Zefr (talk) 14:51, 6 May 2021 (UTC)

[moneymunch] 06/5/2021 17:57

Molecules Review

Potential of Sulforaphane as a Natural Immune System Enhancer:

.................

During the last year, the world has been shocked by the abrupt irruption of COVID-19 and the scientific community has been devoted to find insights that help fight against this disease.

A way to reduce the severity and mortality generated by acute respiratory distress syndrome (ARDS) produced by SARS-COV 2 is to strengthen the immune system.

ARDS produces a dysregulation of the immunological system, and in the most severe cases, the release of pro-inflammatory cytokines and loss of T-cells in the infected organism [52].

There is evidence of the antiviral effect of Nrf2 on respiratory syncytial virus infection [53]and on SARS-COV 1 [54].

Based on information about viruses that belong to the same family, it has been proposed that compounds that activate Nrf2 could probably help to diminish these effects.

Cuadrado et al. [55] suggested that due to its ability to activate Nrf2, induce antioxidant enzymes, reduce pro-inflammatory cytokines, and its efficacy and safety, SFN is a promising candidate to counteract inflammatory reaction and protect lungs from severe damage during SARS COV 2 infection.

Finally, Horowitz and Freeman [56]suggested that clinical trials including administration of Nrf2-activating molecules, such as Molecules of SFN, are imperative to support a possible three-party strategy to fight the COVID-19 pandemic, which includes prevention, diagnostic, and treatment.

[bumpa33] 06/5/2021 10:53

If you google sulforaphane the second top hit is Wikipedia. I’ve edited the ‘Research’ section to bring it up to speed.